Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Etoposide-Carboplatin (EC) Versus EC Plus Endostar in Patients With Extensive Disease Small Cell Lung Cancer (ED-SCLC): Randomized, Open Label, Placebo-controlled, Multicentre Study

NCT00912392 is registered in ClinicalTrials.gov with Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd as lead sponsor.

NCT NCT00912392
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00912392 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Etoposide-Carboplatin (EC) Versus EC Plus Endostar in Patients With Extensive Disease Small Cell Lung Cancer (ED-SCLC): Randomized, Open Label, Placebo-controlled, Multicentre Study
Lead sponsor
Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2009
Completion date
December 31, 2012
Enrollment
138 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer